32.2%, all p B 0.001). MBC patients more frequently had negative ALND (pN0) than non-MBC patients (20.0 vs. 10.6%, p \ 0.001). Among MBC patients, chemotherapy (HR 0.69, 95% CI 0.53-0.89, p = 0.004) and radiotherapy (HR 0.52, 95% CI 0.39-0.69, p \ 0.001) were associated with improved survival, while ALND was associated with decreased survival (HR 1.37, 95% CI 1.06-1.77, p = 0.02). Conclusions. MBC patients had worse survival than non-MBC patients, independent of receptor status, suggesting that MBC may confer an additional survival disadvantage. Multimodal therapy was associated with improved outcomes, but ALND was not and may be overutilized in MBC.
be focal or represent most of the tumor. Because of its heterogeneity, MBC is frequently misdiagnosed or unrecognized on pathologic review. 5 Given the rarity of MBC, much of the relevant literature is comprised of single-institution case series. [6] [7] [8] [9] [10] Previous studies have demonstrated that MBC is less likely to have nodal involvement and more likely to be hormone receptornegative (HR-), larger in size, 11 higher grade, 12 and have a worse prognosis compared with non-MBC. However, it is unclear whether this survival difference is driven by the high rates of HR-status typically observed among MBC cases or whether MBC itself is a poor prognostic indicator. [12] [13] [14] There are no association-endorsed treatment guidelines specific to the management of MBC. In the recently revised National Comprehensive Cancer Network (NCCN) guidelines, metaplastic histology is recognized as an independent, negative prognostic indicator when it accounts for [ 10% of an invasive breast cancer, but no guidance for its treatment is provided. 15 The 2013 St. Gallen consensus statement, which has been adopted by the European Society for Medical Oncology, recommends that MBC patients receive cytotoxic systemic therapy, but mainly because it is often HR-. 16, 17 However, due to evidence of chemoresistance, 2, 18 surgery has often been the mainstay of therapy, 3 and the role of multimodal therapy remains an area of active investigation. In light of its rarity, diagnostic challenges, and unclear treatment guidelines, we sought to identify treatment patterns associated with improved outcome after MBC diagnosis and clinicopathologic features associated with increased likelihood of MBC diagnosis in a contemporary population-based cohort.
METHODS
Females C 18 years of age diagnosed with stage I-III breast cancer between 2010 and 2014 were identified from the National Cancer Data Base (NCDB), which captures more than 70% of all cancers diagnosed in the US. To avoid potential selection bias secondary to sparse coding of human epidermal growth factor receptor 2-positive (HER2 ?) status (i.e. HER2 amplification by fluorescence in situ hybridization [FISH] and/or HER2 protein IHC] ), only patients diagnosed in 2010 (when HER2 coding was standardized by the NCDB 19 ) and later were included. We defined the 'luminal' subtype to include cases that were estrogen receptor (ER)-positive/progesterone receptor (PR)-positive/HER2-, ER?/PR-/HER2-, and ER-/PR?/ HER2-; the 'HER2?' subtype to include cases that were ER?/PR?/HER2?, ER?/PR-/HER2?, ER-/PR?/ HER2?, and ER-/PR-/HER2?; and the 'triple-negative' subtype as ER-/PR-/HER2-. As axillary surgery codes were only recently captured in the NCDB, we used previously described definitions of 1-5 nodes removed and [ 5 lymph nodes removed as proxies for sentinel lymph node biopsy (SLNB) and axillary lymph node dissection (ALND), respectively. 20, 21 Patients with zero or an unknown number of examined lymph nodes, metastatic (stage IV) or non-invasive (stage 0) disease, absent or unknown tumor size, or with a surgical procedure coded as 'none,''local tumor destruction only', 'not otherwise specified', or 'unknown' were excluded, as were patients with unknown or missing survival data. Patients were classified as having MBC or non-MBC based on histologic codes.
Chi square and t-tests were used to compare categorical and continuous variables, respectively. Overall survival (OS) was defined as the time from diagnosis to death or last follow-up. Kaplan-Meier curves were used to visualize unadjusted OS, and the log-rank test was used to test for differences between groups. The Cox proportional hazards model was used to estimate the effect of MBC versus non-MBC histology on OS after adjustment for known covariates. To estimate the effect of covariates on OS within MBC, a subgroup analysis was conducted for MBC patients. Because MBC is often triple negative, a sensitivity survival analysis was conducted with triple-negative breast cancer (TNBC) patients only. To account for the correlation of patients treated at the same facility, a robust sandwich covariance estimator was used for all adjusted survival models. Adjustment variables were chosen based on their association with survival, and select variables were excluded to avoid overfitting the model. We report hazard ratios (HRs) and 95% confidence intervals (CIs) with twotailed p-values; a p value \ 0.05 was considered significant.
A multivariate logistic regression model was used to estimate the association of socioeconomic and pretreatment variables with the odds of being diagnosed with MBC. Odds ratios (ORs) and 95% CIs were reported for each covariate, with two-tailed p \ 0.05 considered significant. Modeling was conducted in the generalized estimating equations framework with an exchangeable correlation structure to account for the correlation of patients treated at the same facility. Multicollinearity among the covariates included in the adjusted models was assessed by examining the variance inflation factor (VIF), tolerance, and condition index for each covariate in the full model. 22 Only patients with complete data were included in each model, and effective sample sizes are included in all tables and figures. No adjustments were made for multiple comparisons. All statistical analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC, USA). Due to the use of de-identified patient data, the Duke University Institutional Review Board granted this study exempt status.
RESULTS
Overall, 2451 MBC patients and 568,057 non-MBC patients were identified from the NCDB ( Table 1 , electronic supplementary Fig. 1 20 .8% of non-MBC patients who underwent NACT (p = 0.25). Although overall radiation use was lower in the MBC population (52.6% MBC vs. 60.9% non-MBC, p \ 0.001), the rates of post-lumpectomy radiation (84.8% MBC vs. 86.9% non-MBC, p = 0.07) between the two groups were comparable. Of note, all patients were included in the analysis of demographic data, but, for the remaining analyses, only patients with complete data were included to allow for adjustment for known covariates. Patient characteristics were compared between those with Out of all patients who were ER? and/or PR?
ALND axillary lymph node dissection, CI confidence interval, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, HR hormone receptor, IQR interquartile range, LN lymph node, NS non-significant, PR progesterone receptor, SLNB sentinel lymph node biopsy, TNBC triple-negative breast cancer ALND axillary lymph node dissection, CI confidence interval, HER2 human epidermal growth factor receptor 2, HR hazard ratio, SLNB sentinel lymph node biopsy, TNBC triple-negative breast cancer comorbidity score, higher pT and pN stages, higher grade, and ALND continued to be associated with worse OS, similar to trends seen in the overall cohort (electronic supplementary Table 2 ). There was an overall association between receptor status and OS (p = 0.03). However, when compared with luminal disease as a reference, OS did not differ significantly for TNBC or HER2? disease. As was seen for the entire cohort, no survival differences were observed between those who received mastectomy vs. lumpectomy (HR 0.79, 95% CI 0.58-1.08, p = 0.14). Given the high rates of triple-negative disease among MBC, we performed a sensitivity survival analysis examining the association between MBC and OS among TNBC patients only. Triple-negative MBC had worse unadjusted OS compared with triple-negative non-MBC (Fig. 2) . This difference persisted after adjustment for covariates (HR 1.49, 95% CI 1.31-1.68, p \ 0.001) [electronic supplementary Table 3 ].
To identify a population of patients for whom there should be a higher suspicion of MBC, multivariate logistic regression analysis was performed ( Analysis of unadjusted overall survival among the subset of triple negative patients demonstrates that metaplastic histology still confers worse survival compared to their non-metaplastic counterparts. CI confidence interval 
DISCUSSION
In our study, the largest contemporary analysis of MBC to include complete hormone and HER2 receptor status information, we confirm that metaplastic histology confers a worse prognosis, even after adjusting for receptor status, and that hormone receptor-positive (HR?) and HER2? breast cancer collectively represent a not insignificant proportion (23.9%) of MBC. Furthermore, we delineate treatment factors associated with improved outcomes.
MBC accounts for \ 1% of all breast cancers, 23 and the rarity of this disease is reflected in the relative paucity of published MBC research. A retrospective review from 2011 found only 19 published articles specific to MBC, 18 of which were case reports or series. 24 In the past decade, there have only been four database studies (electronic supplementary Table 6 ) looking specifically at MBC, which confirmed the worse prognosis of MBC compared with non-MBC but could not evaluate the full influence of receptor status, including HER2. 11, 12, 14, 25 We found that sociodemographic factors, including race, income, education, and insurance status, were associated with MBC diagnosis in univariate analysis, but these associations did not persist in multivariate modeling. Although this could be interpreted as the effect of collinearity, our analysis demonstrated that no significant collinearity existed. Of note, several of these socioeconomic characteristics are also associated with increased incidence of, and worse outcomes following, diagnosis of other aggressive forms of breast cancer, including TNBC and p53-mutated tumors, indicating that these factors may represent non-biologic stressors that contribute to the development of aggressive disease subtypes. 26, 27 Although further investigation is needed to delineate epidemiologic and genetic risk factors for MBC, it is clear from our analysis that triple-negative receptor status is the strongest predictor of MBC. Thus, in TNBC cases involving any clinicopathologic ambiguity, specialized pathologic evaluation may be warranted given the challenges of making a histological diagnosis of MBC and the prognostic implications for failing to do so. This approach would parallel Despite worse outcomes and therapeutic challenges, there are currently no MBC-specific treatment guidelines in the US. Previous studies have yielded conflicting results regarding the effect of breast surgery type on OS. 15, 29 In our study, MBC patients had higher rates of mastectomy than non-MBC patients, but type of surgery was not associated with a survival difference. Concordant with previous studies, a significant proportion of MBC patients presented with node-negative disease, which is in line with its sarcomatoid phenotype and its tendency towards hematogenous rather than lymphatic spread. 3, 30 However, despite this typical presentation, we observed higher rates of ALND, and, more importantly, higher rates of both ALND in cN0 patients (26.4 vs. 22.7%) and negative ALND (i.e. ALND without pathological evidence of nodal involvement in the surgical specimen) in MBC patients compared with non-MBC patients (20.0 vs. 10.6%). As there is variable coding regarding chemotherapy sequence in NCDB, the influence of post-NACT clinical downstaging on the decision to perform ALND cannot be evaluated in the current study. However, the high rate of ALND suggests that, whether NACT was administered or not, surgeons may commit to performing ALND in metaplastic patients regardless of nodal response to NACT. Together, these findings should prompt further investigation regarding the utility of ALND with or without NACT in MBC, whose biology likely predisposes against nodal metastatic spread.
Radiation and chemotherapy were associated with improved OS, in contrast to historical evidence of MBC resistance to non-surgical therapy. 2, 3 We excluded endocrine therapy from multivariate modeling for the TNBCand MBC-only analyses due to low utilization in these TNBC-dominant populations. The NCDB has insufficient granularity to directly compare chemotherapeutic regimens, but previous studies have demonstrated a relative susceptibility to taxane-based chemotherapy and to a regimen consisting of liposomal doxorubicin, bevacizumab, and everolimus. 31 Further studies are needed to elucidate the optimal chemotherapeutic regimen and sequence.
Certain targeted therapies may also be leveraged against MBC. Recent studies have demonstrated frequent overexpression of programmed death-ligand 1 (PD-L1) in MBC, 32 prompting interest in combining checkpoint inhibitors with conventional chemotherapy. 33 There is also emerging evidence that subsets of MBC harbor somatic mutations in the PI3 K, mTOR, and EGFR pathways 34, 35 and have demonstrated favorable responses to corresponding targeted therapies. 36 Application of such novel therapeutics warrants investigation in MBC, an orphan disease with a poor prognosis and limited therapeutic strategies.
Limitations
The limitations of our study are inherent to retrospective analyses of the NCDB. We selected for MBC based on histology codes, but neither the subtype of metaplastic disease nor a central pathologic review of tissue samples was available in this database. The lack of central pathologic review may have artificially increased the number of HR? MBC cases reported in this study compared with prior studies; however, the impact of these potentially misclassified cases on our results and conclusions is mitigated by our including a subgroup analysis restricted to TNBC. The sparse coding of HER2 status before 2009 limited the analysis to patients diagnosed in 2010 and later. Given the unreliable use of axillary surgery codes in the NCDB, we used previously described definitions of 1-5 nodes removed and [ 5 lymph nodes removed as proxies for SLNB and ALND, respectively, although we recognize that lymph node yield may belie the true intent of the operation, and, in some hands, SLNB may yield more lymph nodes than ALND. 20, 21 Finally, the absence of recurrence data in the NCDB limited evaluation of the long-term effects of both locoregional and systemic treatments. Our study paves the way for further institutional analyses, which would allow for central pathologic review and evaluation of long-term, cancer-specific outcomes.
CONCLUSIONS
Our findings corroborate previous studies demonstrating the low likelihood of lymphatic involvement in MBC despite otherwise aggressive disease biology. Importantly, our findings show that despite previous reports of chemoresistance, multimodal therapy is associated with improved outcomes in patients with MBC. In addition, by identifying characteristics associated with MBC, we highlight opportunities to heighten suspicion for and improve the rigor of diagnosis for this condition. Finally, the findings from our study point towards the possibility of a more tailored, potentially less morbid therapeutic approach to MBC that may involve less extensive surgical resection and a larger role for multimodal therapy. Further research into the optimal sequence and composition of therapy is needed and should ultimately be incorporated into association-endorsed guidelines for clinical practice.
